Twenty-eight patients with refractory rheumatoid arthritis completed a randomized 24-week double-blind crossover trial comparing oral methotrexate (2.5 to 5 mg every 12 hours for three doses weekly) with placebo. The methotrexate group had significant reductions (P less than 0.01 as compared with the placebo group) in the number of tender or painful joints, the duration of morning stiffness, and disease activity according to physician and patient assessments at the 12-week crossover visit; reductions in the number of swollen joints (P less than 0.05) and 15-m walking time (P less than 0.03) also occurred. These variables, as well as the grip strength and erythrocyte sedimentation rate, showed significant (P less than 0.01) improvement at 24 weeks in the population crossed over to methotrexate. A significantly increased frequency (P less than 0.03) of the HLA-DR2 haplotype occurred in the eight patients with the most substantial response to methotrexate. Adverse reactions during methotrexate therapy included transaminase elevation (21 per cent), nausea (18 per cent), and diarrhea (12 per cent); one patient was withdrawn from the trial because of diarrhea. One patient died while receiving the placebo. Methotrexate did not affect measures of humoral or cellular immunity. We conclude that this trial provides evidence of the short-term efficacy of methotrexate in rheumatoid arthritis, but the mechanism of action is unknown. Longer trials will be required to determine the ultimate safety and effectiveness of this drug.
This article has been cited by other articles:
Cohen, J., Calabresi, P., Chakraborty, S., Edwards, K., Eickenhorst, T., Felton, W. III, Fisher, E., Fox, R., Goodman, A., Hara-Cleaver, C., Hutton, G., Imrey, P., Ivancic, D., Mandell, B., Perryman, J., Scott, T., Skaramagas, T., Zhang, H. for the AC
(2008). Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. Mult Scler
14: 370-382
[Abstract]
van der Kooij, S. M, de Vries-Bouwstra, J. K, Goekoop-Ruiterman, Y. P M, van Zeben, D., Kerstens, P. J S M, Gerards, A. H, van Groenendael, J. H L M, Hazes, J. M W, Breedveld, F. C, Allaart, C. F, Dijkmans, B. A C
(2007). Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis
66: 1356-1362
[Abstract][Full Text]
Luo, G., Garner, C. E., Xiong, H., Hu, H., Richards, L. E., Brouwer, K. L. R., Duan, J., Decicco, C. P., Maduskuie, T., Shen, H., Lee, F. W., Gan, L.-S.
(2007). Effect of DPC 333 [(2R)-2-{(3R)-3-Amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a Human Tumor Necrosis Factor {alpha}-Converting Enzyme Inhibitor, on the Disposition of Methotrexate: A Transporter-Based Drug-Drug Interaction Case Study. Drug Metab. Dispos.
35: 835-840
[Abstract][Full Text]
Combe, B, Landewe, R, Lukas, C, Bolosiu, H D, Breedveld, F, Dougados, M, Emery, P, Ferraccioli, G, Hazes, J M W, Klareskog, L, Machold, K, Martin-Mola, E, Nielsen, H, Silman, A, Smolen, J, Yazici, H
(2007). EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis
66: 34-45
[Abstract][Full Text]
Uga, H., Kuramori, C., Ohta, A., Tsuboi, Y., Tanaka, H., Hatakeyama, M., Yamaguchi, Y., Takahashi, T., Kizaki, M., Handa, H.
(2006). A New Mechanism of Methotrexate Action Revealed by Target Screening with Affinity Beads. Mol. Pharmacol.
70: 1832-1839
[Abstract][Full Text]
Pincus, T., Sokka, T.
(2006). Should aggressive therapy for rheumatoid arthritis require early use of weekly low-dose methotrexate, as the first disease-modifying anti-rheumatic drug in most patients?. Rheumatology (Oxford)
45: 497-499
[Full Text]
Cronstein, B N
(2006). Going with the flow: methotrexate, adenosine, and blood flow. Ann Rheum Dis
65: 421-422
[Full Text]
Weinblatt, M E
(2005). Will our current success in treating rheumatoid arthritis hinder new drug development? That is the question!!. Ann Rheum Dis
64: 1529-1531
[Full Text]
Dervieux, T, Furst, D, Lein, D O, Capps, R, Smith, K, Caldwell, J, Kremer, J
(2005). Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis
64: 1180-1185
[Abstract][Full Text]
Doan, T., Massarotti, E.
(2005). Rheumatoid Arthritis: An Overview of New and Emerging Therapies. J Clin Pharmacol
45: 751-762
[Abstract][Full Text]
Cronstein, B. N.
(2005). Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis. Pharmacol. Rev.
57: 163-172
[Abstract][Full Text]
Wolf, J, Stranzl, T, Filipits, M, Pohl, G, Pirker, R, Leeb, B, Smolen, J S
(2005). Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis. Ann Rheum Dis
64: 564-568
[Abstract][Full Text]
Liu, M., Ge, Y., Cabelof, D. C., Aboukameel, A., Heydari, A. R., Mohammad, R., Matherly, L. H.
(2005). Structure and Regulation of the Murine Reduced Folate Carrier Gene: IDENTIFICATION OF FOUR NONCODING EXONS AND PROMOTERS AND REGULATION BY DIETARY FOLATES. J. Biol. Chem.
280: 5588-5597
[Abstract][Full Text]
Hartmann, S. N, Rordorf, C. M, Milosavljev, S., Branson, J. M, Chales, G. H, Juvin, R. R, Lafforgue, P., Le Parc, J. M., Tavernier, C. G, Meyer, O. C
(2004). Lumiracoxib Does Not Affect Methotrexate Pharmacokinetics in Rheumatoid Arthritis Patients. The Annals of Pharmacotherapy
38: 1582-1587
[Abstract][Full Text]
Courtemanche, C., Elson-Schwab, I., Mashiyama, S. T., Kerry, N., Ames, B. N.
(2004). Folate Deficiency Inhibits the Proliferation of Primary Human CD8+ T Lymphocytes In Vitro. J. Immunol.
173: 3186-3192
[Abstract][Full Text]
Elewaut, D.
(2004). Right on target: coupling methotrexate to albumin to treat rheumatoid arthritis. Rheumatology (Oxford)
43: 1067-1068
[Full Text]
Yocum, D. E., Furst, D. E., Bensen, W. G., Burch, F. X., Borton, M. A., Mengle-Gaw, L. J., Schwartz, B. D., Wisememandle, W., Mekki, Q. A.
(2004). Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford)
43: 992-999
[Abstract][Full Text]
O'Dell, J. R.
(2004). Therapeutic Strategies for Rheumatoid Arthritis. NEJM
350: 2591-2602
[Full Text]
Hochberg, M C, Tracy, J K, Hawkins-Holt, M, Flores, R H
(2003). Comparison of the efficacy of the tumour necrosis factor {alpha} blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis
62: ii13-16
[Abstract][Full Text]
Weinblatt, M E
(2003). Rheumatoid arthritis in 2003: where are we now with treatment?. Ann Rheum Dis
62: ii94-96
[Full Text]
Harris, J. P., Weisman, M. H., Derebery, J. M., Espeland, M. A., Gantz, B. J., Gulya, A. J., Hammerschlag, P. E., Hannley, M., Hughes, G. B., Moscicki, R., Nelson, R. A., Niparko, J. K., Rauch, S. D., Telian, S. A., Brookhouser, P. E.
(2003). Treatment of Corticosteroid-Responsive Autoimmune Inner Ear Disease With Methotrexate: A Randomized Controlled Trial. JAMA
290: 1875-1883
[Abstract][Full Text]
Dervieux, T., Orentas Lein, D., Marcelletti, J., Pischel, K., Smith, K., Walsh, M., Richerson, R.
(2003). HPLC Determination of Erythrocyte Methotrexate Polyglutamates after Low-Dose Methotrexate Therapy in Patients with Rheumatoid Arthritis. Clin. Chem.
49: 1632-1641
[Abstract][Full Text]
Aletaha, D, Stamm, T, Kapral, T, Eberl, G, Grisar, J, Machold, K P, Smolen, J S
(2003). Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis
62: 944-951
[Abstract][Full Text]
Ranganathan, P, Eisen, S, Yokoyama, W M, McLeod, H L
(2003). Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?. Ann Rheum Dis
62: 4-9
[Abstract][Full Text]
Pincus, T., Ferraccioli, G., Sokka, T., Larsen, A., Rau, R., Kushner, I., Wolfe, F.
(2002). Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford)
41: 1346-1356
[Abstract][Full Text]
Aletaha, D., Smolen, J. S.
(2002). The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology (Oxford)
41: 1367-1374
[Abstract][Full Text]
van Ede, A. E., Laan, R. F. J. M., Blom, H. J., Boers, G. H. J., Haagsma, C. J., Thomas, C. M. G., de Boo, T. M., van de Putte, L. B. A.
(2002). Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford)
41: 658-665
[Abstract][Full Text]
Rau, R., Herborn, G., Menninger, H., Sangha, O.
(2002). Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology (Oxford)
41: 196-204
[Abstract][Full Text]
Hochberg, M C, Tracy, J K, Flores, R H
(2001). ""Stepping-up"" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate. Ann Rheum Dis
60: iii51-54
[Full Text]
CUTOLO, M, SULLI, A, PIZZORNI, C, SERIOLO, B, STRAUB, R H
(2001). Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis
60: 729-735
[Full Text]
Rampton, D S
(2001). Methotrexate in Crohn's disease. Gut
48: 790-791
[Full Text]
Izeradjene, K., Revillard, J.-P., Genestier, L.
(2001). Inhibition of thymidine synthesis by folate analogues induces a Fas-Fas ligand-independent deletion of superantigen-reactive peripheral T cells. Int Immunol
13: 85-93
[Abstract][Full Text]
Lipsky, P. E., van der Heijde, D. M.F.M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., Harriman, G. R., Maini, R. N., The Anti-Tumor Necrosis Factor Trial in Rheumatoid,
(2000). Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. NEJM
343: 1594-1602
[Abstract][Full Text]
Feagan, B. G., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Koval, J., Wong, C. J., Hopkins, M., Hanauer, S. B., McDonald, J. W.D., The North American Crohn's Study Group Investigato,
(2000). A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease. NEJM
342: 1627-1632
[Abstract][Full Text]
Seitz, M., Dayer, J.-M.
(2000). Enhanced production of tissue inhibitor of metalloproteinases by peripheral blood mononuclear cells of rheumatoid arthritis patients responding to methotrexate treatment. Rheumatology (Oxford)
39: 637-645
[Abstract][Full Text]
Lerndal, T., Svensson, B.
(2000). A clinical study of CPH 82 vs methotrexate in early rheumatoid arthritis. Rheumatology (Oxford)
39: 316-320
[Abstract][Full Text]
Strand, V., Cohen, S., Schiff, M., Weaver, A., Fleischmann, R., Cannon, G., Fox, R., Moreland, L., Olsen, N., Furst, D., Caldwell, J., Kaine, J., Sharp, J., Hurley, F., Loew-Friedrich, I., for the Leflunomide Rheumatoid Arthritis Investiga,
(1999). Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate. Arch Intern Med
159: 2542-2550
[Abstract][Full Text]
Pincus, T., O'Dell, J. R., Kremer, J. M.
(1999). Combination Therapy with Multiple Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Preventive Strategy. ANN INTERN MED
131: 768-774
[Abstract][Full Text]
Smolenska, Z., Kaznowska, Z., Zarowny, D., Simmonds, H. A., Smolenski, R. T.
(1999). Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology (Oxford)
38: 997-1002
[Abstract][Full Text]
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., Burge, D. J.
(1999). A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate. NEJM
340: 253-259
[Abstract][Full Text]
Neidel, J., Sova, L., Schroers, B., Sintermann, F., Manzke, O., Bohlen, H.
(1998). Effects of methotrexate on normal articular cartilage in vitro and in vivo. Ann Rheum Dis
57: 414-421
[Abstract][Full Text]
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., Widmer, M. B., Blosch, C. M.
(1997). Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein. NEJM
337: 141-147
[Abstract][Full Text]
O'Dell, J. R., Haire, C. E., Erikson, N., Drymalski, W., Palmer, W., Eckhoff, P. J., Garwood, V., Maloley, P., Klassen, L. W., Wees, S., Klein, H., Moore, G. F.
(1996). Treatment of Rheumatoid Arthritis with Methotrexate Alone, Sulfasalazine and Hydroxychloroquine, or a Combination of All Three Medications. NEJM
334: 1287-1291
[Abstract][Full Text]
Feagan, B. G., Rochon, J., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Gillies, R., Hopkins, M., Hanauer, S. B., McDonald, J. W.D., The North American Crohn's Study Group Investigato,
(1995). Methotrexate for the Treatment of Crohn's Disease. NEJM
332: 292-297
[Abstract][Full Text]
Weinblatt, M. E.
(1995). Methotrexate for Chronic Diseases in Adults. NEJM
332: 330-331
[Full Text]
Cash, J. M., Klippel, J. H.
(1994). Second-Line Drug Therapy for Rheumatoid Arthritis. NEJM
330: 1368-1375
[Full Text]
Trentham, D., Dynesius-Trentham, R., Orav, E., Combitchi, D, Lorenzo, C, Sewell, K., Hafler, D., Weiner, H.
(1993). Effects of oral administration of type II collagen on rheumatoid arthritis. Science
261: 1727-1730
[Abstract]
Previous
